Axon Therapies has closed a $32 million Series A round that was oversubscribed, signaling strong investor confidence in medtech solutions targeting heart failure. The raise was co-led by Earlybird Venture Capital and Santé Ventures, with additional backing from Deerfield Management, CD Capital, and KOFA Healthcare.
The company’s lead innovation is Splanchnic Ablation for Volume Management (SAVM), a procedure that shifts excess blood volume from the heart into the abdominal circulation. This reduces fluid overload and pulmonary capillary wedge pressure—two of the core physiological drivers of heart failure. Unlike traditional device-based therapies, SAVM is implant-free and minimally invasive, designed to address both Heart Failure with Preserved Ejection Fraction (HFpEF) and Heart Failure with Reduced Ejection Fraction (HFrEF).
With fresh funding, Axon plans to advance its pivotal trials. One will focus on SAVM for HFpEF, a condition affecting nearly half of heart failure patients worldwide and one with limited effective treatment options. Another trial will expand research into its use for HFrEF, which has different disease dynamics but remains a leading cause of hospitalization.
The company also announced leadership changes. Cofounder and former chief scientific officer Zoar Engelman has stepped into the role of CEO. Engelman emphasized that the funding allows the team to move forward with large-scale validation. “Our implant-free, minimally invasive therapy is designed to address a core physiological driver of the disease. This funding positions us to advance to pivotal trials and bring hope to patients who urgently need new solutions,” he said.
Telehealth Firm Caregility Expands with $25.1 Million Raise
Telehealth platform Caregility secured $25.1 million in additional funding through Series A-2 Preferred Stock and Series C rounds, bringing its total raised capital to $92 million. Star Mountain Capital led the round, with contributions from management, founding stakeholders, and high-net-worth investors focused on healthcare technology.
The company’s platform enables enterprise-level telehealth deployments, with a strong presence in hospital-based virtual care. A significant portion of the new capital will fund the development of artificial intelligence features, including edge-based computer vision, ambient listening tools, and sensor-based detection technologies designed to improve patient safety and clinical efficiency.
Dr. David Shulkin, former U.S. Secretary of Veterans Affairs and an independent board member at Caregility, noted that the company’s innovations are setting a new benchmark. “Caregility is setting the standard for innovation in hospital-based virtual care, with groundbreaking capabilities such as edge-based Computer Vision AI and audio sensing room duress detection,” Shulkin said. He added that these tools are already being deployed globally.
Daymark Health Raises $20 Million to Advance Hybrid Cancer Care
Daymark Health, a company offering hybrid cancer care services, raised $20 million in its Series A round. Healthier Capital led the investment, supported by Blue Venture Fund and returning backers Maverick Ventures, Yosemite, and Oncology Ventures.
Daymark delivers both virtual and in-home services for cancer patients, addressing not only clinical needs but also social and mental health factors. Its model involves direct partnerships with health plans, ensuring that oncologists and primary care physicians can coordinate more effectively around a patient’s needs.
With the new capital, Daymark plans to scale its platform nationwide, focusing on new payer and provider partnerships. The company’s expansion comes at a time when oncology care systems are under pressure to deliver more comprehensive support to patients outside hospital walls.
AmplifyMD Secures $20 Million to Enhance Hospital Virtual Care
AmplifyMD, a California-based virtual care platform launched in 2019, raised $20 million in its Series B round. Forerunner Ventures led the investment, joined by Memorial Hermann Health System, F-Prime, Greylock, and Tau Ventures.
AmplifyMD specializes in providing on-demand specialty coverage for hospitals and health systems. The funding will be used to expand artificial intelligence–enabled workflows and enhance clinical integration features that make specialist access more seamless.
According to Feby Abraham, executive vice president and chief strategy officer at Memorial Hermann, AmplifyMD offers a fundamentally different approach. “AmplifyMD stands out because it combines AI-enabled workflows with on-demand specialty coverage, creating a scalable model that expands access, improves quality, and lowers costs,” Abraham said.
Broader Funding Wave in Digital Health
The flurry of funding announcements reflects broader momentum in digital health and medtech investment. Venture capitalists are increasingly prioritizing solutions that improve access, efficiency, and outcomes in high-cost conditions such as cardiovascular disease and cancer, as well as platforms that modernize hospital operations.
The deals also underscore a trend: investors are backing companies that integrate artificial intelligence into their clinical workflows, whether through imaging, computer vision, ambient monitoring, or workflow automation. This shift signals confidence that AI, when coupled with scalable platforms, can generate cost savings while supporting overburdened clinical staff.
Other recent deals in the sector reinforce the pattern. Sleep technology firm Sunrise Group raised $29 million, while cancer-focused Thyme Care secured $97 million and reported profitability. Voice AI company Prosper AI closed a $5 million round to expand its health-focused platform.
Looking Ahead
The four companies—Axon Therapies, Caregility, Daymark Health, and AmplifyMD—represent different slices of the healthcare ecosystem but share a common thread: they are all targeting system-level pain points. From Axon’s novel heart failure treatment to Caregility’s AI-driven hospital monitoring, Daymark’s integrated oncology care, and AmplifyMD’s specialist access model, each is addressing gaps that existing healthcare infrastructure struggles to fill.
Their success in raising capital reflects investor belief in a more tech-enabled, patient-centered healthcare landscape. With global healthcare systems facing rising demand, constrained budgets, and clinician shortages, these models are likely to see accelerated adoption.
For health systems, payers, and policymakers, the challenge will be to evaluate how such technologies scale in diverse care settings and how reimbursement policies adapt to support them. For patients, the promise lies in earlier intervention, improved access to specialists, and more comprehensive care beyond the hospital.
The funding wave highlights not only the resilience of digital health but also its evolution—from point solutions to integrated, AI-powered systems with the potential to transform patient outcomes at scale.
